Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCYC NASDAQ:IGMS NASDAQ:NVCT NASDAQ:PALI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$4.00-0.1%$4.60$3.95▼$9.18$279.24M1.54518,819 shs317,575 shsIGMSIGM Biosciences$1.27$1.28$1.08▼$1.47$76.57M0.6535,598 shsN/ANVCTNuvectis Pharma$13.82$10.03$5.55▼$14.16$366.58M-0.0799,126 shs323,266 shsPALIPalisade Bio$1.87$1.97$0.53▼$2.86$324.59M1.522.59 million shs4.04 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics0.00%-1.36%-9.62%-8.16%-46.09%IGMSIGM Biosciences0.00%0.00%0.00%0.00%+8.55%NVCTNuvectis Pharma0.00%+29.04%+30.01%+67.92%+71.68%PALIPalisade Bio0.00%+9.36%-0.53%-1.06%+191.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCYCBicycle Therapeutics$4.00-0.1%$4.60$3.95▼$9.18$279.24M1.54518,819 shs317,575 shsIGMSIGM Biosciences$1.27$1.28$1.08▼$1.47$76.57M0.6535,598 shsN/ANVCTNuvectis Pharma$13.82$10.03$5.55▼$14.16$366.58M-0.0799,126 shs323,266 shsPALIPalisade Bio$1.87$1.97$0.53▼$2.86$324.59M1.522.59 million shs4.04 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCYCBicycle Therapeutics0.00%-1.36%-9.62%-8.16%-46.09%IGMSIGM Biosciences0.00%0.00%0.00%0.00%+8.55%NVCTNuvectis Pharma0.00%+29.04%+30.01%+67.92%+71.68%PALIPalisade Bio0.00%+9.36%-0.53%-1.06%+191.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCYCBicycle Therapeutics 2.44Hold$14.00250.44% UpsideIGMSIGM Biosciences 0.00N/AN/AN/ANVCTNuvectis Pharma 2.00Hold$13.00-5.93% DownsidePALIPalisade Bio 2.88Moderate Buy$10.20445.45% UpsideCurrent Analyst Ratings BreakdownLatest IGMS, NVCT, PALI, and BCYC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2026NVCTNuvectis Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $13.006/9/2026PALIPalisade Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/5/2026NVCTNuvectis Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/3/2026BCYCBicycle Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform4/30/2026BCYCBicycle Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/10/2026BCYCBicycle Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/9/2026PALIPalisade Bio Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.004/8/2026BCYCBicycle Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$13.00 ➝ $12.004/8/2026PALIPalisade Bio Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.003/26/2026PALIPalisade Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.00(Data available from 6/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCYCBicycle Therapeutics$63.50M4.39N/AN/A$8.79 per share0.45IGMSIGM Biosciences$145.05M0.53N/AN/A$1.67 per share0.76NVCTNuvectis PharmaN/AN/AN/AN/A$0.72 per shareN/APALIPalisade Bio$250K1,298.38N/AN/A$0.87 per share2.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCYCBicycle Therapeutics-$218.96M-$3.15N/AN/AN/A-344.95%-35.74%-29.54%8/14/2026 (Estimated)IGMSIGM Biosciences-$195.79M-$0.90N/AN/AN/A-36.81%-93.35%-24.15%N/ANVCTNuvectis Pharma-$26.44M-$1.31N/AN/AN/AN/A-161.00%-98.88%8/4/2026 (Estimated)PALIPalisade Bio-$16.78M-$1.01N/AN/AN/AN/A-36.79%-34.34%8/10/2026 (Estimated)Latest IGMS, NVCT, PALI, and BCYC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026PALIPalisade Bio-$0.04-$0.05-$0.01-$0.05N/AN/A5/5/2026Q1 2026NVCTNuvectis Pharma-$0.30-$0.26+$0.04-$0.26N/AN/A4/30/2026Q1 2026BCYCBicycle Therapeutics-$0.6209-$0.87-$0.2491-$0.87$7.50 million$0.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBCYCBicycle TherapeuticsN/AN/AN/AN/AN/AIGMSIGM BiosciencesN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/APALIPalisade BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCYCBicycle TherapeuticsN/A12.6612.66IGMSIGM BiosciencesN/A17.6617.66NVCTNuvectis PharmaN/A2.272.27PALIPalisade BioN/A23.7123.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCYCBicycle Therapeutics86.15%IGMSIGM Biosciences42.79%NVCTNuvectis Pharma96.77%PALIPalisade Bio11.79%Insider OwnershipCompanyInsider OwnershipBCYCBicycle Therapeutics22.90%IGMSIGM Biosciences57.00%NVCTNuvectis Pharma28.55%PALIPalisade Bio0.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCYCBicycle Therapeutics24069.81 million53.82 millionOptionableIGMSIGM Biosciences19060.29 million25.93 millionOptionableNVCTNuvectis Pharma826.53 million18.95 millionNot OptionablePALIPalisade Bio10173.58 million173.46 millionNot OptionableIGMS, NVCT, PALI, and BCYC HeadlinesRecent News About These CompaniesPalisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of DirectorsJune 11, 2026 | globenewswire.comPalisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences SymposiumJune 9, 2026 | markets.businessinsider.comPalisade Bio, Inc. to Present on PDE4 Inhibitor Prodrug Approach for Fibrostenotic Crohn's Disease at NYAS SymposiumJune 9, 2026 | quiverquant.comQPalisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences SymposiumJune 9, 2026 | globenewswire.comPalisade Bio (PALI) Gets a Buy from B. Riley SecuritiesJune 7, 2026 | theglobeandmail.comPalisade Bio to Participate in the Jefferies Global Healthcare ConferenceMay 27, 2026 | globenewswire.comPalisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4MMay 18, 2026 | finance.yahoo.comWe're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash BurnMay 16, 2026 | finance.yahoo.comPalisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108May 12, 2026 | globenewswire.comPalisade Bio reports phase 1a/b data showing colon‑targeted exposureMay 5, 2026 | pharmatimes.comPPalisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative ColitisMay 5, 2026 | globenewswire.comPalisade Bio (PALI) price target decreased by 12.09% to 10.20April 29, 2026 | msn.comWolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical ProfileApril 17, 2026 | insidermonkey.comPalisade Bio, Inc. Announces Poster Presentation at Digestive Disease Week® 2026 Featuring PALI-2108 Data on Ulcerative ColitisApril 16, 2026 | quiverquant.comQPalisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026April 16, 2026 | globenewswire.comWolfe Research initiates coverage of Palisade Bio (PALI) with outperform recommendationApril 10, 2026 | msn.comPalisade Bio to Present at the Needham & Co. 25th Annual Healthcare ConferenceApril 8, 2026 | globenewswire.comPalisade Bio partners with Iterative Health to advance PALI-2108April 2, 2026 | tipranks.comPalisade Bio drops after early-stage trial data for lead assetMarch 31, 2026 | msn.comPalisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s DiseaseMarch 30, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIGMS, NVCT, PALI, and BCYC Company DescriptionsBicycle Therapeutics NASDAQ:BCYC$4.00 -0.01 (-0.13%) Closing price 06/18/2026 03:59 PM EasternExtended Trading$3.98 -0.01 (-0.25%) As of 06/18/2026 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.IGM Biosciences NASDAQ:IGMSIGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.Nuvectis Pharma NASDAQ:NVCT$13.82 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$13.85 +0.03 (+0.22%) As of 06/18/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Palisade Bio NASDAQ:PALI$1.87 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$1.86 -0.01 (-0.27%) As of 06/18/2026 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
